세계의 흑색종 치료제 시장 (2023-2030) : 제품별 (화학 요법, 면역 요법), 약물 유형별 (브랜드 의약품, 제네릭 의약품), 지역별

■ 영문 제목 : Melanoma Therapeutics Market Size, Share & Trends Analysis Report By Product (Chemotherapy, Immunotherapy), By Drug Type (Branded Drugs, Generic Drugs), By Region, And Segment Forecasts, 2023 - 2030

Grand View Research 회사가 출판한 조사자료로, 코드는 GRV23NOV209 입니다.■ 상품코드 : GRV23NOV209
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 9월
■ 페이지수 : 100
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 의료 기기
■ 판매가격 / 옵션 (부가세 10% 별도)
Single User (1인 열람용)USD5,950 ⇒환산￦8,032,500견적의뢰/주문/질문
Multi User (5인 열람용)USD6,950 ⇒환산￦9,382,500견적의뢰/주문/질문
Global/corporate License (기업 열람용)USD8,950 ⇒환산￦12,082,500견적의뢰/구입/질문
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
글로벌 흑색종 치료제 시장의 성장과 동향
Grand View Research사의 최신 보고서에 따르면, 세계의 흑색종 치료제 시장 규모는 2030년까지 109억 8천만 달러에 달할 것으로 예상되며, 2023년부터 2030년까지 연평균 10. 3%의 성장률을 기록할 것으로 예측됩니다. 흑색종, 피부암, 피부 알레르기 등 만성 질환의 발병률 증가는 시장의 중요한 촉진 요인입니다.

CDC에 따르면 2013년 71,943명 이상이 흑색종에 걸렸다고 합니다. 미국 암 협회는 이 숫자가 2017년에는 87,100명으로 증가할 것으로 추정하고 있으며, 이는 예측 기간 동안 흑색종 치료제의 필요성을 강조하고 있습니다.

FDA 승인 건수의 증가와 효능이 향상된 새로운 치료제의 등장도 성장 기회를 제공할 것으로 예상되며, 2011년부터 2016년까지 6년간 옵디보, 여보이, 코텔릭, 젤보라프, 키트루다, 메퀴니스트, 타핀라, 임리직 등 8개의 생물학적 제제가 이 질환의 치료제로 승인됐습니다.

각 회사는 기존 제품의 새로운 적응증 발굴과 혁신적인 분자 개발을 위해 다양한 연구개발 활동을 진행하고 있습니다. 예를 들어, 2014년 9월 미국 FDA는 전이성 흑색종 치료제인 키트루다(Merck & Co., Inc.)를 비소세포폐암 치료제로 승인한 바 있습니다.

또한 미국, 유럽, 아시아 태평양 지역의 많은 제약사들이 새로운 생물학적 제제 개발에 주력하고 있습니다. 예를 들어, 다이이찌산쿄(Daiichi Sankyo Corporation)는 2017년 3월 공동연구를 통한 신약개발을 촉진하기 위해 'Take a New Challenge for Drug discovery(TaNeDS)'라는 공동창작 프로젝트를 발표했습니다. 또한, AgonOX, Inc. 와 전략적 연구 제휴를 체결하여 면역 및 암 영역의 신규 면역치료제 개발을 추진하고 있습니다. 예측 기간 동안 새로운 제품이 승인되면 시장 성장을 촉진할 것으로 예상됩니다.

흑색종 치료제 시장 보고서 하이라이트

- 표적치료제 분야는 부작용이 적고 효율성이 높다는 장점으로 인해 예측 기간 동안 11. 9%의 높은 성장률을 기록할 것으로 추청하고 있습니다.

- 특허에 의한 독점권으로 인해 브랜드 의약품은 2022년 91. 33%의 업계 점유율을 차지할 것으로 예상됩니다.

- 옵디보와 코텔릭과 같은 생물학적 제제는 채택 증가와 치료 효과 향상 등의 장점으로 인해 예측 기간 동안 유리한 성장을 보일 것으로 예상됩니다.

- 야보이의 특허는 미국에서는 2022년, 유럽에서는 2020년에 만료됩니다. 이는 신규 진입 기업들에게 성장 기회를 제공할 것으로 예상됩니다.

- 아시아 태평양 지역은 예측 기간 동안 11. 6%의 유리한 CAGR을 보일 것으로 예상됩니다.

- 주요 기업들은 흑색종 치료를 위한 신약 발견 및 개발을 위한 R&D 노력을 강화하고 있다고 전했습니다.
■ 보고서 개요

Chapter 1. 조사 방법 및 범위
Chapter 2. 개요
Chapter 3. 시장 변동, 동향, 범위
Chapter 4. 세계의 흑색종 치료제 시장 : 제품별 예측 및 동향 분석
Chapter 5. 세계의 흑색종 치료제 시장 : 약제 유형별 예측 및 동향 분석
Chapter 6. 세계의 흑색종 치료제 시장 : 지역별 예측 및 동향 분석
Chapter 7. 경쟁 현황

■ 보고서 목차

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Drug type
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Drug type outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Melanoma Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market drivers analysis
3.3.2. Market restraints analysis
3.4. Melanoma Therapeutics Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Melanoma Therapeutics: Product Estimates & Trend Analysis
4.1. Melanoma Therapeutics Market: Key Takeaways
4.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Chemotherapy
4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Immunotherapy
4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Targeted Therapy
4.5.1. Targeted therapy estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Radiation Therapy
4.6.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Melanoma Therapeutics: Drug Type Estimates & Trend Analysis
5.1. Melanoma Therapeutics Market: Key Takeaways
5.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Branded Drugs
5.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Generic Drugs
5.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Melanoma Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Melanoma Therapeutics Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Bristol-Myers Squibb Company
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. AstraZeneca
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Novartis AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Merck & Co, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Amgen Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. F. Hoffman-La Roche Ltd.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Abbott Laboratories.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives=

List of Tables

Table 1 List of Abbreviation
Table 2 North America melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 3 North America melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 4 North America melanoma therapeutics market, by region, 2018 – 2030 (USD Million)
Table 5 U.S. melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 6 U.S. melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 7 Canada melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 8 Canada melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 9 Europe melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 10 Europe melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 11 Europe melanoma therapeutics market, by region, 2018 – 2030 (USD Million)
Table 12 Germany melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 13 Germany melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 14 UK melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 15 UK melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 16 France melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 17 France melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 18 Italy melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 19 Italy melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 20 Spain melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 21 Spain melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 22 Sweden melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 23 Sweden melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 24 Norway melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 25 Norway melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 26 Denmark melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 27 Denmark melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 28 Asia Pacific melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 29 Asia Pacific melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 30 Asia Pacific melanoma therapeutics market, by region, 2018 – 2030 (USD Million)
Table 31 China melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 32 China melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 33 Japan melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 34 Japan melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 35 India melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 36 India melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 37 Thailand melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 38 Thailand melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 39 South Korea melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 40 South Korea melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 41 Latin America melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 42 Latin America melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 43 Latin America melanoma therapeutics market, by region, 2018 – 2030 (USD Million)
Table 44 Brazil melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 45 Brazil melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 46 Mexico melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 47 Mexico melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 48 Argentina melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 49 Argentina melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 50 Middle East and Africa melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 51 Middle East and Africa melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 52 Middle East and Africa melanoma therapeutics market, by region, 2018 – 2030 (USD Million)
Table 53 South Africa melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 54 South Africa melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 55 Saudi Arabia melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 56 Saudi Arabia melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 57 UAE melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 58 UAE melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 59 Kuwait melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 60 Kuwait melanoma therapeutics market, by drug type, (USD Million) 2018 – 2030Report SummaryTable of ContentsSegmentationMethodologyRequest a FREE Sample Copy
Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Drug type
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Drug type outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Melanoma Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market drivers analysis
3.3.2. Market restraints analysis
3.4. Melanoma Therapeutics Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Melanoma Therapeutics: Product Estimates & Trend Analysis
4.1. Melanoma Therapeutics Market: Key Takeaways
4.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Chemotherapy
4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Immunotherapy
4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Targeted Therapy
4.5.1. Targeted therapy estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Radiation Therapy
4.6.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Melanoma Therapeutics: Drug Type Estimates & Trend Analysis
5.1. Melanoma Therapeutics Market: Key Takeaways
5.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Branded Drugs
5.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Generic Drugs
5.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Melanoma Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Melanoma Therapeutics Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Bristol-Myers Squibb Company
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. AstraZeneca
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Novartis AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Merck & Co, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Amgen Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. F. Hoffman-La Roche Ltd.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Abbott Laboratories.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 3 North America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 4 North America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 6 U.S. melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 7 Canada melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 8 Canada melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 9 Europe melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 10 Europe melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 11 Europe melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 12 Germany melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 13 Germany melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 14 UK melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 15 UK melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 16 France melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 17 France melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 18 Italy melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 19 Italy melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 20 Spain melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 21 Spain melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 22 Sweden melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 23 Sweden melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 24 Norway melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 25 Norway melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 26 Denmark melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 27 Denmark melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 28 Asia Pacific melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 29 Asia Pacific melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 30 Asia Pacific melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 31 China melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 32 China melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 33 Japan melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 34 Japan melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 35 India melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 36 India melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 37 Thailand melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 38 Thailand melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 39 South Korea melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 40 South Korea melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 41 Latin America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 42 Latin America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 43 Latin America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 44 Brazil melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 45 Brazil melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 46 Mexico melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 47 Mexico melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 48 Argentina melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 49 Argentina melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 50 Middle East and Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 51 Middle East and Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 53 South Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 54 South Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 55 Saudi Arabia melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 56 Saudi Arabia melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 57 UAE melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 58 UAE melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 59 Kuwait melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 60 Kuwait melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
보고서 이미지

※본 조사보고서 [세계의 흑색종 치료제 시장 (2023-2030) : 제품별 (화학 요법, 면역 요법), 약물 유형별 (브랜드 의약품, 제네릭 의약품), 지역별] (코드 : GRV23NOV209) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [세계의 흑색종 치료제 시장 (2023-2030) : 제품별 (화학 요법, 면역 요법), 약물 유형별 (브랜드 의약품, 제네릭 의약품), 지역별] 에 대해서 E메일 문의는 여기를 클릭하세요.
*** 아래는 관련 보고서 소개입니다 ***

  • 세계의 T세포 치료 시장 (2023-2030) : 치료법별 (CAR-T세포, 종양 침윤 림프구), 질환별 (혈액 악성 종양 (림프종))
    GRV23MR041 / Grand View Research / 2023년 2월 / Grand View Research사의 본 조사 보고서는 글로벌 T세포 치료 시장 규모가 2023년부터 2030년 사이에 CAGR 17.6% 증가하여, 2030년에는 308.3억 달러에 달할 것으로 전망하고 있습니다. 본 조사 자료는 글로벌 T세포 치료...T-cell Therapy Market Growth & Trends The global T-cell therapy market size is expected to reach USD 30.83 billion by 2030 and is expected to register a CAGR of 17.6% from 2023 to 2030 according to a new report by Grand View Research, Inc. The landmark approval of Kymriah and...
  • 세계의 약물 유전체학 시장 (2023-2030) : 치료 영역별, 기술별 (PCR, ISH, 면역 조직 화학, 시퀀싱, 기타), 지역별
    GRV23NOV180 / Grand View Research / 2023년 9월 / 글로벌 약물 유전체학 시장의 성장과 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 약물 유전체학 시장 규모는 2023년부터 2030년까지 연평균 8. 7%의 성장률로 확대되어 2030년에는 123억 달러에 달할 것으로 예상됩니다....Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변동, 동향, 범위 Chapter 4. 세계의 약물 유전체학 시장 : 치료 영역별 예측 및 동향 분석 Chapter 5. 세계의 약물 유전체학 시장 : 기술별 예측 및 동향 분석 Chapter 6. 세계의 약물 유전체학 시장 : 지역별 예측 및...
  • 세계의 지혈대 시스템 시장 (2023-2030) : 구성 요소별 (지혈대 기기, 지혈대 커프), 용도별 (병원, 외래), 지역별
    GRV23NOV248 / Grand View Research / 2023년 9월 / 글로벌 지혈대 시스템 시장의 성장 및 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 지혈대 시스템 시장 규모는 2023년부터 2030년까지 연평균 7. 9%의 성장률을 기록하여 2030년에는 8억7330만 달러에 달할 것으로...Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변동, 동향, 범위 Chapter 4. 세계의 지혈대 시스템 시장 : 구성 요소별 예측 및 동향 분석 Chapter 5. 세계의 지혈대 시스템 시장 : 용도별 예측 및 동향 분석 Chapter 6. 세계의 지혈대 시스템 시장 : 지역별 예측 및...
  • 세계의 전립선암 진단 시장 (2023-2030) : 검사 유형별 (예비, 확증), 유형별 (선암종, 간질 세포 암종), 용도별 (병원, 외래 환자 시설), 지역별
    GRV23NOV181 / Grand View Research / 2023년 9월 / 글로벌 전립선암 진단 시장의 성장과 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 전립선암 진단 시장 규모는 2023년부터 2030년까지 연평균 6. 23%의 성장률로 확대되어 2030년에는 131억 6천만 달러에 달할 것으로...Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변동, 동향, 범위 Chapter 4. 세계의 전립선암 진단 시장 : 검사 유형별 예측 및 동향 분석 Chapter 5. 세계의 전립선암 진단 시장 : 유형별 예측 및 동향 분석 Chapter 6. 세계의 전립선암 진단 시장 : 최종 용도별 예측...
  • 세계의 수술용 붐 시장 (2023-2030) : 제품 유형별 (기기용 붐, 마취용 붐, 기타 붐), 설치별, 최종 용도별, 지역별
    GRV23NOV246 / Grand View Research / 2023년 9월 / 글로벌 수술용 붐 시장의 성장과 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 수술용 붐 시장 규모는 2030년까지 6억 1837만 달러에 달할 것으로 예상되며, CAGR은 5. 21%를 기록할 것으로 추정됩니다....Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변동, 동향, 범위 Chapter 4. 세계의 수술용 붐 시장 : 제품 유형별 예측 및 동향 분석 Chapter 5. 세계의 수술용 붐 시장 : 설치별 예측 및 동향 분석 Chapter 6. 세계의 수술용 붐 시장 : 최종 용도별 예측...

    • ※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!